PB1864: BRUIN CLL-321: A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF PIRTOBRUTINIB VS INVESTIGATOR’S CHOICE OF IDELALISIB+RITUXIMAB OR BENDAMUSTINE+RITUXIMAB IN BTKI PRETREATED CLL/SLL (TRIAL IN PROGRESS)

• J. P. Sharman,
• W. Jurczak,
• C. C. Coombs,
• M. Hill,
• D. Wang,
• N. C. Ku,
• A. Guntur,
• S. Shahda,
• C. C. Leow,
• P. Ghia,
• A. R. Mato

Affiliations

J. P. Sharman

1 Willamette Valley Cancer Institute and Research Center, US Oncology Research, Eugene, United States of America

W. Jurczak

2 Maria Sklodowska-Curie National Research Institute of Oncology, Krakow, Poland

C. C. Coombs

3 University of North Carolina at Chapel Hill, Chapel Hill

M. Hill

4 Loxo Oncology at Lilly, Stamford, United States of America

D. Wang

4 Loxo Oncology at Lilly, Stamford, United States of America

N. C. Ku

4 Loxo Oncology at Lilly, Stamford, United States of America

A. Guntur

4 Loxo Oncology at Lilly, Stamford, United States of America

S. Shahda

4 Loxo Oncology at Lilly, Stamford, United States of America

C. C. Leow

4 Loxo Oncology at Lilly, Stamford, United States of America

P. Ghia

5 Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele, Milan, Italy

A. R. Mato

6 Memorial Sloan Kettering Cancer Center, New York, United States of America